• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    January 22, 2021 - Coronavirus (COVID-19) Update: January 22, 2021

    1/22/21 3:54:10 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care
    Get the next $MMM alert in real time by email
    For Immediate Release:
    January 22, 2021

    The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

    • The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found that in a variety of online postings from as early as March 2020, the defendant, Johnny T. Stine, claimed to have a COVID-19 vaccine that he offered to inject in customers for $400-$1000 each. Stine’s company, North Coast Biologics, had previously received a warning letter from the agency for promoting an unapproved COVID-19 vaccine product.

      “Unproven injectable vaccines purported to prevent or treat COVID-19, made from unknown substances under unknown conditions, present significant health risks in and of themselves. They also can lead consumers to make lifestyle choices that increase their actual risk of infection with COVID-19, or to delay or stop appropriate medical treatment,” said Special Agent in Charge Lisa L. Malinowski, FDA Office of Criminal Investigations Los Angeles Field Office. “The FDA will continue to investigate fraudulent COVID-19 treatments and bring to justice those who try to profit from the pandemic by offering unproven and illegally marketed coronavirus products.”
    • The FDA is reissuing the Emergency Use Authorizations (EUAs) for decontamination systems that are authorized to decontaminate compatible N95 respirators for use by healthcare personnel (HCP) to prevent exposure to pathogenic biological airborne particulates when there is an insufficient supply of new respirators resulting from the Coronavirus Disease 2019 (COVID-19) pandemic. Among other things, the reissued EUAs for certain decontamination systems are now only authorized to decontaminate each compatible N95 respirator a maximum of four or fewer times.

      Based on the FDA’s review of real-world use of these systems and evidence from adverse events and scientific literature, including studies regarding N95 respirator failures from simulated and real-world use, the FDA has determined that it is appropriate to protect the public health or safety to revise certain decontamination system EUAs to limit the number of decontamination cycles and respirator reuses permitted under each authorization.
    • Today, the FDA also added two new devices to the device discontinuance list on our web page that lists medical device shortages during the COVID-19 public health emergency. There are no updates to the device shortage list at this time. The FDA will continue to update the device shortage and device discontinuance lists as the COVID-19 public health emergency evolves. Specifically, the FDA added the following devices to the device discontinuance list:
      • 3M Company's 3M Triple Layer Molded Face Mask (2042F) and 3M Triple Layer Molded Face Mask, Petite (2042FP)
      • BioFire Diagnostics, LLC's FilmArray Instrument (FLM1-ASY-0001)
    • Testing updates:
      • As of today, 319 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 237 molecular tests and sample collection devices, 69 antibody tests, and 13 antigen tests. There are 33 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, one antigen prescription at-home test, and one over-the-counter (OTC) at-home antigen test.

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

    ###


    Inquiries

    Media:
    Abby Capobianco
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

    Related Information

    Related Information
    • FAQs on Testing for SARS-CoV-2
    • Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)
    • Coronavirus Disease 2019 (COVID-19)

    Get the next $MMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MMM

    DatePrice TargetRatingAnalyst
    7/17/2026$180.00Neutral → Overweight
    Analyst
    6/15/2026$190.00Buy
    Goldman
    6/10/2026$131.00Underperform
    Bernstein
    1/16/2026$182.00Overweight → Neutral
    Analyst
    12/8/2025$178.00Buy → Hold
    Deutsche Bank
    10/22/2025$160.00Underweight → Equal-Weight
    Morgan Stanley
    1/22/2025$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    11/13/2024$184.00Neutral → Buy
    UBS
    More analyst ratings

    $MMM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 22, 2021 - Coronavirus (COVID-19) Update: January 22, 2021

    For Immediate Release: January 22, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found th

    1/22/21 3:54:10 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    3M upgraded by Analyst with a new price target

    Analyst upgraded 3M from Neutral to Overweight and set a new price target of $180.00

    7/17/26 8:16:24 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on 3M with a new price target

    Goldman resumed coverage of 3M with a rating of Buy and set a new price target of $190.00

    6/15/26 8:11:43 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Bernstein initiated coverage on 3M with a new price target

    Bernstein initiated coverage of 3M with a rating of Underperform and set a new price target of $131.00

    6/10/26 8:40:45 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MMM
    SEC Filings

    View All

    3M Reports Second-Quarter 2026 Results; Increases Full-Year Guidance

    Q2 GAAP sales of $6.5 billion, up 2.4%; operating margin of 15.1%, down 290 bps; EPS of $1.78, up 33%, all YoY Adjusted sales of $6.5 billion with organic growth of 5.4% YoYAdjusted operating margin of 24.9%, up 40 bps YoYAdjusted EPS of $2.40, up 11% YoYQ2 operating cash flow of $1.0 billion with adjusted free cash flow of $1.3 billion2026 adjusted EPS guidance increased from $8.50 - $8.70 to $8.80 - $8.95ST. PAUL, Minn., July 21, 2026 /PRNewswire/ -- 3M (NYSE:MMM) today reported second-quarter results."We delivered a strong second quarter, exceeding expectations with mid-single-digit sales growth, robust operating margins of about 25%, and double-digit EPS growth, reflecting the progress w

    7/21/26 6:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M and Microsoft announce strategic partnership to advance AI data center infrastructure and enterprise transformation

    Microsoft becomes first announced hyperscale cloud provider to deploy 3M Expanded Beam Optical (EBO) technology 3M to use Microsoft AI and digital capabilities to advance enterprise transformation across key functions ST. PAUL, Minn. and REDMOND, Wash., July 15, 2026 /PRNewswire/ -- 3M (NYSE:MMM) and Microsoft (NASDAQ:MSFT) today announced a strategic partnership focused on AI data center infrastructure and enterprise transformation. Microsoft's Azure Cloud and AI Infrastructure will become the first announced hyperscale cloud provider to deploy 3M's Expanded Beam Optical (EBO) technology. 3M will also use Microsoft's AI and digital platforms as part of its enterprise transformation across k

    7/15/26 9:01:00 AM ET
    $MMM
    $MSFT
    Medical/Dental Instruments
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Scotch™ Brand launches Scotch Kids® Tape for young creators

    New kid-friendly collection supports hands-on creativity, crafting and building for children ages four and upST. PAUL, Minn., July 14, 2026 /PRNewswire/ -- Scotch™ Brand has launched Scotch® Kids Tape to help children create, craft and share their creativity. Designed for kids ages four and up, Scotch® Kids Tape supports crafting, decorating and building projects for young creators. The new line encourages children to confidently apply their imagination and bring their biggest ideas to life with simple materials and without the mess of glue."Kids are natural creators, builders and problem-solvers," said Amanda Dauphiniais, vice

    7/14/26 7:46:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Group President Bauer Wendy A exercised 7,952 shares at a strike of $159.96 and covered exercise/tax liability with 3,558 shares, increasing direct ownership by 94% to 9,086 units (SEC Form 4)

    4 - 3M CO (0000066740) (Issuer)

    7/2/26 9:13:09 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Director Rumsey Jennifer was granted 1,196 shares (SEC Form 4)

    4 - 3M CO (0000066740) (Issuer)

    6/9/26 4:07:08 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Rumsey Jennifer

    3 - 3M CO (0000066740) (Issuer)

    6/9/26 4:04:16 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by 3M Company

    144 - 3M CO (0000066740) (Subject)

    7/22/26 1:41:07 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by 3M Company

    10-Q - 3M CO (0000066740) (Filer)

    7/21/26 12:08:01 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - 3M CO (0000066740) (Filer)

    7/21/26 6:34:07 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Leadership Updates

    Live Leadership Updates

    View All

    3M Announces New Board Appointment

    Jennifer Rumsey, Chair and Chief Executive Officer of Cummins Inc., elected to the Board of DirectorsBrings deep experience leading a global industrial technology companyST. PAUL, Minn., June 8, 2026 /PRNewswire/ -- 3M (NYSE:MMM) announced today the election of Jennifer W. Rumsey to 3M's Board of Directors, effective June 5, 2026. Ms. Rumsey also has been appointed as a member of the Science, Technology and Sustainability Committee of the Board."Jennifer is a highly regarded leader with deep experience driving growth across global industrial markets through innovation and technology," said William M. Brown, 3M's Chairman and Chief Executive Officer. "She will bring valuable perspective to ou

    6/8/26 11:00:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Annual Meeting Results

    ST. PAUL, Minn., May 12, 2026 /PRNewswire/ -- At today's Annual Meeting of Shareholders, 3M (NYSE:MMM) shareholders overwhelmingly supported each of the proposals recommended for approval by the company.Preliminary Shareholder Voting Results3M shareholders today voted on the following business items:1) Shareholders supported 10 directors for one-year terms:David P. Bozeman, President, Chief Executive Officer and Director, C.H. Robinson Worldwide, Inc.Thomas "Tony" K. Brown, retired Group Vice President, Global Purchasing, Ford Motor CompanyWilliam M. "Bill" Brown, Chairman of the Board and Chief Executive Officer, 3M CompanyAudrey Choi, retired Chief Sustainability Officer and Management Com

    5/12/26 4:46:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M appoints Meagan Linn as Senior Vice President, Government Affairs

    ST. PAUL, Minn., Feb. 16, 2026 /PRNewswire/ -- 3M today announced the appointment of Meagan Linn as Senior Vice President, Government Affairs. In this role, Linn will oversee the company's engagement with the executive branch, policymakers, regulatory agencies, and industry associations, globally to advance public policy dialogue. She will also be responsible for developing business growth through government contracts. Linn brings 20 years of experience in public policy, with 12 years at Northrop Grumman Corporation, most recently as government policy lead and Chief of Staff, an

    2/16/26 10:00:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Financials

    Live finance-specific insights

    View All

    3M Reports Second-Quarter 2026 Results; Increases Full-Year Guidance

    Q2 GAAP sales of $6.5 billion, up 2.4%; operating margin of 15.1%, down 290 bps; EPS of $1.78, up 33%, all YoY Adjusted sales of $6.5 billion with organic growth of 5.4% YoYAdjusted operating margin of 24.9%, up 40 bps YoYAdjusted EPS of $2.40, up 11% YoYQ2 operating cash flow of $1.0 billion with adjusted free cash flow of $1.3 billion2026 adjusted EPS guidance increased from $8.50 - $8.70 to $8.80 - $8.95ST. PAUL, Minn., July 21, 2026 /PRNewswire/ -- 3M (NYSE:MMM) today reported second-quarter results."We delivered a strong second quarter, exceeding expectations with mid-single-digit sales growth, robust operating margins of about 25%, and double-digit EPS growth, reflecting the progress w

    7/21/26 6:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Announces Upcoming Investor Event

    ST. PAUL, Minn., July 7, 2026 /PRNewswire/ -- 3M (NYSE: MMM) today announced the following investor event:Second-quarter 2026 earnings conference call on Tuesday, July 21, 2026, at 8 a.m. CT.This event will be webcast live and a replay will be available on 3M's Investor Relations website at http://investors.3M.com.About 3M3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M

    7/7/26 10:15:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Board Declares Quarterly Dividend

    ST. PAUL, Minn., May 12, 2026 /PRNewswire/ -- The 3M Company Board of Directors (NYSE:MMM) today declared a dividend on the company's common stock of $0.78 per share for the second quarter of 2026. The dividend is payable June 12, 2026, to shareholders of record at the close of business on May 22, 2026.3M has paid dividends to its shareholders without interruption for more than 100 years.About 3M3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footpri

    5/12/26 5:01:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/13/24 4:56:03 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/9/23 10:54:46 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/9/22 3:15:56 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care